ClinicalTrials.gg
RecruitingNCT05356741Updated Nov 12, 2026

To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

A Phase 1/2 interventional study of VIR-5818 and pembrolizumab in Locally Advanced or Metastatic HER2-Expressing Cancers, sponsored by Vir Biotechnology, Inc.. Recruiting at 13 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Vir Biotechnology, Inc. · Phase 1/2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.
Updated Nov 12, 20263 sites added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
645
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This first-in-human (FIH) Phase 1 open-label multicenter dose-escalation and dose-expansion study is designed to evaluate the safety, pharmacokinetics, and preliminary activity of VIR-5818 (Formerly AMX-818) as a single agent and in combination with pembrolizumab in participants with HER2+ tumors across multiple tumor types. The study will be conducted in four parts:

  • Part 1 (dose escalation): Single-agent VIR-5818
  • Part 2 (dose escalation): VIR-5818 plus pembrolizumab
  • Part 3 (dose expansion): Single-agent VIR-5818
  • Part 4 (dose expansion): VIR-5818 plus pembrolizumab

The total length of the study, from screening of the first participant to the end of the study, is expected to be approximately 72 months.

02

Conditions studied

  • Locally Advanced or Metastatic HER2-Expressing Cancers
03

In context

Lead sponsor

Vir Biotechnology, Inc. is the lead sponsor of 22 studies on the registry; 2 are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 11 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written by the participant (or legally acceptable representative if applicable)
  • of at least 12 weeks
  • (ECOG) performance status of 0 or 1
  • Diseases under study, , and human epidermal growth factor receptor 2 () status, per local tests

Exclusion criteria

Exclusion criteria:

  • Significant cardiopulmonary disease and recent cardiac events
  • History of major organ diseases
  • Acute or chronic infections

The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
645 participants (estimated)

Study arms

  • Experimental
    Part 1 (dose escalation)

    Participants will receive single-agent VIR-5818

    Drug: VIR-5818

  • Experimental
    Part 2 (dose escalation)

    Participants will receive VIR-5818 plus pembrolizumab

    Drug: VIR-5818 · Drug: pembrolizumab

  • Experimental
    Part 3 (dose expansion)

    Participants will receive single-agent VIR-5818

    Drug: VIR-5818

  • Experimental
    Part 4 (dose expansion

    Participants will receive VIR-5818 plus pembrolizumab

    Drug: VIR-5818 · Drug: pembrolizumab

Interventions

  • DrugVIR-5818

    Administered as IV infusion

  • Administered as IV infusion

    Also known as: KEYTRUDA®

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicity - Part 1 and Part 2

    Time frame: Up to approximately 21 days (Part 1) and 42 days (Part 2)

  2. Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)- Parts 1, 2, 3, and 4

    Time frame: Up to approximately 55 months

  3. Objective Response Rate (ORR) - Part 3 and Part 4

    ORR defined as a Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1.

    Time frame: Up to approximately 55 months

  4. Duration of Response (DOR) - Part 3 and Part 4

    DOR defined as the time from the first occurrence of a documented objective response to the time of the first documented disease progression or death from any cause, whichever occurs first, per RECIST v.1.1.

    Time frame: Up to approximately 55 months

Secondary outcomes

  1. ORR - Part 3 and Part 4

    ORR defined as defined as a Complete Response (CR) or Partial Response (PR) per Immune Response Evaluation Criteria in Solid Tumors (iRECIST).

    Time frame: Up to approximately 55 months

  2. DOR - Part 3 and Part 4

    DOR defined as the time from the first occurrence of a documented objective response to the time of the first documented disease progression or death from any cause, whichever occurs first, per iRECIST.

    Time frame: Up to approximately 55 months

  3. Pharmacokinetics (PK) parameter: Area under the concentration-time curve (AUC)

    Time frame: Predose, intermediate timepoints at multiple cycles (1 Cycle = 21 days) up to approximately 55 months

  4. PK parameter: Maximum plasma concentration (Cmax)

    Time frame: Predose, intermediate timepoints at multiple cycles (1 Cycle = 21 days) up to approximately 55 months

  5. PK parameter: Minimum serum concentration (Cmin)

    Time frame: Predose, intermediate timepoints at multiple cycles (1 Cycle = 21 days) up to approximately 55 months

  6. PK parameter: Clearance (CL)

    Time frame: Predose, intermediate timepoints at multiple cycles (1 Cycle = 21 days) up to approximately 55 months

  7. PK parameter: Volume of distribution at steady-state (Vss)

    Time frame: Predose, intermediate timepoints at multiple cycles (1 Cycle = 21 days) up to approximately 55 months

  8. PK parameter: Accumulation ratio

    Time frame: Predose, intermediate timepoints at multiple cycles (1 Cycle = 21 days) up to approximately 55 months

  9. PK parameter: Half-life (t1/2)

    Time frame: Predose, intermediate timepoints at multiple cycles (1 Cycle = 21 days) up to approximately 55 months

  10. Incidence of anti-drug antibodies (ADAs) to VIR-5818

    Time frame: Multiple timepoints at specified cycles (1 Cycle = 21 days) up to approximately 55 months

  11. All parts: Disease control rate (DCR)

    defined as CR+PR+ Stable Disease (SD) per RECIST v 1.1

    Time frame: Up to approximately 55 months

07

Study locations

12 of 13 sites recruiting
  • Investigational site number #450
    Duarte, California 91010, United States
    Recruiting
  • Investigational site number #451
    Palo Alto, California 94305, United States
    Recruiting
  • Investigational site number #100
    Melbourne, Victoria 3000, Australia
    Active, not recruiting

    Not enrolling at this site.

  • Investigational site number #101
    Randwick, 2031, Australia
    Recruiting
  • Investigational site number #150
    Toulouse, 31059, France
    Recruiting
  • Investigational site number #200
    Porto, 4200-072, Portugal
    Recruiting
  • Investigational site number #255
    Barcelona, 08023, Spain
    Recruiting
  • Investigational site number #251
    Barcelona, 08035, Spain
    Recruiting
  • Investigational site number #254
    Madrid, 28027, Spain
    Recruiting
  • Investigational site number #257
    Madrid, 28034, Spain
    Recruiting
  • Investigational site number #252
    Madrid, 28050, Spain
    Recruiting
  • Investigational site number #250
    Pamplona, 31008, Spain
    Recruiting
  • Investigational site number #253
    Pozuelo de Alarcón, 28223, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for Apr 2028, 72 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2022
First posted
May 2, 2022
StartActual
Apr 13, 2022
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 2 sites removed
Show 3 added (2 United States, 1 Spain)
  • Investigational site number #450 · Duarte, United States
  • Investigational site number #451 · Palo Alto, United States
  • Investigational site number #257 · Madrid, Spain
Show 2 removed
  • City of Hope National Medical Center · Duarte, United States
  • Investigational site number #257 · Madrid, Spain
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    3 sites added, 2 sites removed
    Show 3 added (2 United States, 1 Spain)
    • Investigational site number #450 · Duarte, United States
    • Investigational site number #451 · Palo Alto, United States
    • Investigational site number #257 · Madrid, Spain
    Show 2 removed
    • City of Hope National Medical Center · Duarte, United States
    • Investigational site number #257 · Madrid, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05356741
Responsible party
Sponsor
First posted
May 2, 2022
Start date
Apr 13, 2022
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Study Inquiry
Contact
clinicaltrials@vir.bio
415-654-5281

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion